Spectral Med Inc (EDT : TSX)
Common Stock
$1.39
CAD
+0.00 (%)
Last updated: 2026-06-03
EDT
Spectral Med Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
-2.11%
1 Month
-2.11%
YTD
+0.72%
Key Statistics
Market Cap
$407.85M
52W High
$1.76
52W Low
$0.77
P/E Ratio
-
50 Day MA
$1.40
200 Day MA
$1.39
Beta
0.17
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/3/2026 | $1.41 | $1.41 | $1.39 | $1.39 | $1.39 | 35,916 |
| 6/2/2026 | $1.41 | $1.41 | $1.39 | $1.39 | $1.39 | 35,355 |
| 6/1/2026 | $1.41 | $1.41 | $1.39 | $1.41 | $1.41 | 18,419 |
| 5/29/2026 | $1.43 | $1.44 | $1.38 | $1.42 | $1.42 | 83,684 |
| 5/28/2026 | $1.42 | $1.42 | $1.38 | $1.40 | $1.40 | 42,268 |
| 5/27/2026 | $1.42 | $1.43 | $1.39 | $1.42 | $1.42 | 80,568 |
| 5/26/2026 | $1.45 | $1.45 | $1.39 | $1.42 | $1.42 | 61,940 |
| 5/25/2026 | $1.42 | $1.43 | $1.40 | $1.43 | $1.43 | 63,920 |
| 5/22/2026 | $1.41 | $1.42 | $1.38 | $1.42 | $1.42 | 31,088 |
| 5/21/2026 | $1.38 | $1.42 | $1.37 | $1.38 | $1.38 | 158,862 |
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 126.6% over the next 12 months.
Consensus
No RatingAvg. Target
C$3.15
+126.6% Upside
Current Price
C$1.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
32.2%
Annualized
90-Day Vol
37.9%
Annualized
Trend (90d)
+28.1%
Annualized drift
90d Mean
C$1.54
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.44 | C$1.29 โ C$1.61 |
| 60 trading days | C$1.49 | C$1.27 โ C$1.74 |
| 90 trading days | C$1.54 | C$1.27 โ C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Spectral Med Inc
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $2.76M
- EBITDA
- $-10.66M
- Profit Margin
- 0.00%
- ROE (TTM)
- -973.97%
- EPS (Diluted)
- -0.13
- Book Value
- -0.24
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE Report